Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances
Confirms Trial Weighted Towards Overall Survival Endpoint
Executive Summary
Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.
You may also be interested in...
Roche Is ‘Aiming For The Sky’ With Vabysmo Commercial Launch
CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.
Roche Diagnostics CEO Schinecker Will Succeed Schwan As A New Chapter Unfolds
The Swiss drug maker is preparing for a smooth transition in 2023, appointing 20-year Roche veteran and diagnostic chief Thomas Schinecker as its next chief executive as Severin Schwan becomes chairman.
Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.